Resectable Stage I-III Non-Small Cell Lung Cancer (NSCLC) research hub

A Phase I-II, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients with Resectable Stage I-III Non-Small Cell Lung Cancer, selected according to Biomarker Status

This study is testing whether giving targeted medicine and chemotherapy before surgery helps people with early to mid-stage non-small cell lung cancer. Researchers want to see if matching medicines to a tumour's specific biology can safely shrink the cancer and make surgery more successful.